JGH: 胆囊切除术可降低复杂胆结石患者发生胆管癌的风险

2021-12-24 MedSci原创 MedSci原创

胆结石是世界范围的常见病。在我国自然人群中,胆结石的发病率达10%左右。女性患者多见,尤其是较肥胖的女性,男女之比约为1∶2。胆结石是胆管(胆囊)癌的致病因素。

胆结石是世界范围的常见病。在我国自然人群中,胆结石的发病率达10%左右。女性患者多见,尤其是较肥胖的女性,男女之比约为1∶2。胆结石是胆管(胆囊)癌的致病因素之一。据报道,胆结石与肝胆癌呈正相关。然而,胆囊切除术或复杂胆结石患者患这些癌症的风险是有争议的。 本项研究旨在探究胆囊切除术对胆结石和复杂胆结石亚组患者胆管癌 (CCA) 或肝细胞癌 (HCC) 风险的影响。

 

研究人员使用韩国国民健康保险数据库确纳入了胆结石患者 (n=958,677) 和年龄和性别匹配的对照患者 (n=9,586,770)。复杂性胆结石定义为与急性胆囊炎或急性胆管炎相关的胆结石。与对照组相比,研究人员在接受胆囊切除术的胆结石患者中评估了 CCA 和 HCC 发生率的风险比(aHR,95% CI),并且还分析了这些对复杂胆结石患者的影响。

 

研究结果显示与对照组相比,胆结石患者的 CCA (1.80, 1.67-1.93) 和 HCC (1.03, 1.00-1.07) 风险明显增加。与未进行胆囊切除术的患者相比,胆囊切除术对 CCA (1.94, 1.76-2.14) 和 HCC (0.93, 0.87-0.99) 的风险影响最小。然而,复杂胆结石患者的 CCA 风险显着增加 (5.62, 4.89-6.46),胆囊切除术后风险降低 30% (3.91, 3.43-4.46)。与肝内 CCA 或 Vater 壶腹癌相比,胆囊切除术对肝外 CCA 的风险降低更大。然而,与对照组相比,复杂胆结石患者和接受胆囊切除术的患者的 HCC 风险没有差异。

 

最后研究人员最后说道:复杂性胆结石患者发生 CCA 的风险显着增加,胆囊切除术可部分降低 CCA 风险,但是胆结石或胆囊切除术的 HCC 风险变化很小。

原始出处:

Hyeong Sik Ahn. Et al. Cholecystectomy reduces the risk of cholangiocarcinoma in patients with complicated gallstones, but has negligible effect on hepatocellular carcinoma. Journal of Gastroenterology and Hepatology.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1679016, encodeId=290316e901639, content=<a href='/topic/show?id=df0a834328b' target=_blank style='color:#2F92EE;'>#胆囊切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83432, encryptionId=df0a834328b, topicName=胆囊切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d227724361, createdName=huangshifeng, createdTime=Tue Nov 29 01:38:45 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877530, encodeId=0da118e753094, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Apr 20 22:38:45 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429805, encodeId=2208142980557, content=<a href='/topic/show?id=140783434c7' target=_blank style='color:#2F92EE;'>#胆囊切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83434, encryptionId=140783434c7, topicName=胆囊切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3f94230600, createdName=yangfl07, createdTime=Fri Dec 24 12:38:45 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628502, encodeId=02341628502bd, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Fri Dec 24 12:38:45 CST 2021, time=2021-12-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1679016, encodeId=290316e901639, content=<a href='/topic/show?id=df0a834328b' target=_blank style='color:#2F92EE;'>#胆囊切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83432, encryptionId=df0a834328b, topicName=胆囊切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d227724361, createdName=huangshifeng, createdTime=Tue Nov 29 01:38:45 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877530, encodeId=0da118e753094, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Apr 20 22:38:45 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429805, encodeId=2208142980557, content=<a href='/topic/show?id=140783434c7' target=_blank style='color:#2F92EE;'>#胆囊切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83434, encryptionId=140783434c7, topicName=胆囊切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3f94230600, createdName=yangfl07, createdTime=Fri Dec 24 12:38:45 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628502, encodeId=02341628502bd, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Fri Dec 24 12:38:45 CST 2021, time=2021-12-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1679016, encodeId=290316e901639, content=<a href='/topic/show?id=df0a834328b' target=_blank style='color:#2F92EE;'>#胆囊切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83432, encryptionId=df0a834328b, topicName=胆囊切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d227724361, createdName=huangshifeng, createdTime=Tue Nov 29 01:38:45 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877530, encodeId=0da118e753094, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Apr 20 22:38:45 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429805, encodeId=2208142980557, content=<a href='/topic/show?id=140783434c7' target=_blank style='color:#2F92EE;'>#胆囊切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83434, encryptionId=140783434c7, topicName=胆囊切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3f94230600, createdName=yangfl07, createdTime=Fri Dec 24 12:38:45 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628502, encodeId=02341628502bd, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Fri Dec 24 12:38:45 CST 2021, time=2021-12-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1679016, encodeId=290316e901639, content=<a href='/topic/show?id=df0a834328b' target=_blank style='color:#2F92EE;'>#胆囊切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83432, encryptionId=df0a834328b, topicName=胆囊切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d227724361, createdName=huangshifeng, createdTime=Tue Nov 29 01:38:45 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877530, encodeId=0da118e753094, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Apr 20 22:38:45 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429805, encodeId=2208142980557, content=<a href='/topic/show?id=140783434c7' target=_blank style='color:#2F92EE;'>#胆囊切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83434, encryptionId=140783434c7, topicName=胆囊切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3f94230600, createdName=yangfl07, createdTime=Fri Dec 24 12:38:45 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628502, encodeId=02341628502bd, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Fri Dec 24 12:38:45 CST 2021, time=2021-12-24, status=1, ipAttribution=)]

相关资讯

Lancet Oncol:Ivosidenib显著改善晚期mIDH1胆管癌患者的生存率

Tibsovo(Ivosidenib)艾伏尼布(AG-120) , 是靶向异柠檬酸脱氢酶1(IDH1)突变的口服、强效的抑制剂。而IDH1突变在多种肿瘤中均有发生。2018年7月20日获FDA批准上市

Sci Transl Med:重大进展!王红阳院士团队揭示胆管癌精准治疗新策略

胆管癌恶性程度高,进展快,临床就诊时多属晚期,且多已复发转移,可手术率低;常规放化疗对胆管癌的疗效非常有限,在其他肿瘤中已显示明确疗效的靶向治疗、免疫治疗等手段在胆管癌中的尝试也鲜见成功例子。

Lancet Gastroenterol Hepatol:Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性

Infigratinib在既往治疗过的具有FGFR2基因融合或重排的局部晚期或转移性胆管癌患者中具有良好的临床活性和可控制的不良事件

Int J Cancer:意外发现:AGEs摄入量与肝癌风险呈负相关!

与预期相反,在一项大型跨国队列研究中,较高的晚期糖基化终末产物(AGEs)膳食摄入量,包括来自油炸、烤制或烤制食品中的AGEs,与肝细胞癌(HCC)风险下降相关。

Pemigatinib治疗FGFR2融合或重排的晚期胆管癌,CHMP持积极评价

人用药品委员会(CHMP)对pemigatinib治疗无法切除的局部晚期或转移性胆管癌持积极意见,建议批准上市。